Abstract | PURPOSE: PATIENTS AND METHODS: Patients from 86 centers worldwide were randomly assigned to receive either goserelin (3.6 mg every 28 days for 2 years; n = 514) or CMF (six 28-day cycles; n = 496), and were included in the QoL study. QoL was assessed using a self-administered patient questionnaire that consisted of 39 items from the Rotterdam Symptom Checklist, including dimensions evaluating physical and psychological symptom distress, activities of daily living, hormonal effects, and an assessment of overall QoL. RESULTS: Early benefits were noted during months 3 to 6 of treatment, for goserelin compared with CMF. Significant differences were found for changes in overall QoL (eg, 6.96 +/- 0.88 v 0.69 +/- 0.92 at 6 months; P <.0001) and for physical symptom distress, activity levels, and "effort to cope with illness" dimensions. At 1, 2, and 3 years, there were no significant differences in overall QoL or specific QoL dimensions. Scores for hormonal symptoms were worse with goserelin during the 2-year goserelin treatment period; however, this trend was reversed at 3 years. CONCLUSION:
|
Authors | H de Haes, M Olschewski, M Kaufmann, M Schumacher, W Jonat, W Sauerbrei, Zoladex Early Breast Cancer Research Association Trialists Group |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 21
Issue 24
Pg. 4510-6
(Dec 15 2003)
ISSN: 0732-183X [Print] United States |
PMID | 14610048
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Goserelin
- Cyclophosphamide
- Fluorouracil
- Methotrexate
|
Topics |
- Adult
- Antineoplastic Agents, Hormonal
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Breast Neoplasms
(drug therapy, pathology)
- Climacteric
- Cyclophosphamide
(administration & dosage)
- Factor Analysis, Statistical
- Female
- Fluorouracil
(administration & dosage)
- Goserelin
(therapeutic use)
- Humans
- Lymphatic Metastasis
- Methotrexate
(administration & dosage)
- Middle Aged
- Premenopause
- Quality of Life
- Surveys and Questionnaires
|